JNJ

186.06

-1.55%↓

ABT

123.82

+0.19%↑

TMO

564.44

-0.63%↓

ISRG

544.18

+1.83%↑

DHR

214.06

-0.72%↓

JNJ

186.06

-1.55%↓

ABT

123.82

+0.19%↑

TMO

564.44

-0.63%↓

ISRG

544.18

+1.83%↑

DHR

214.06

-0.72%↓

JNJ

186.06

-1.55%↓

ABT

123.82

+0.19%↑

TMO

564.44

-0.63%↓

ISRG

544.18

+1.83%↑

DHR

214.06

-0.72%↓

JNJ

186.06

-1.55%↓

ABT

123.82

+0.19%↑

TMO

564.44

-0.63%↓

ISRG

544.18

+1.83%↑

DHR

214.06

-0.72%↓

JNJ

186.06

-1.55%↓

ABT

123.82

+0.19%↑

TMO

564.44

-0.63%↓

ISRG

544.18

+1.83%↑

DHR

214.06

-0.72%↓

Inicio・Lista de Acciones・West Pharmaceutical Services Inc

West Pharmaceutical Services Inc

Cerrado

SectorSanidad

279.45 -0.98

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

273.99

Máximo

282.22

Métricas clave
By Trading Economics
Ingresos	8.2M 140M
Ventas	38M 804M
P/B Media del Sector	44.052 37.003
BPA	1.96
Rentabilidad por dividendo	0.28
Margen de beneficios	17.406
Empleados	10,600
EBITDA	17M 215M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+23.24% upside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	0.28% 2.25%
Fecha Próximo Dividendo	19 nov 2025
Próxima Fecha de Ex Dividendo	12 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	1.6B 21B
Apertura anterior	280.43
Cierre anterior	279.45

Noticias sobre sentimiento de mercado

By Acuity

50%

142 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

213.26 / 219.27 Soporte y Resistencia

West Pharmaceutical Services Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 nov 2025, 22:13 UTC

Ganancias

Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update

2 nov 2025, 21:23 UTC

Ganancias

Westpac Raises Dividend Despite 1% Slip in Annual Profit

2 nov 2025, 23:43 UTC

Charlas de Mercado

Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk

2 nov 2025, 23:34 UTC

Charlas de Mercado

Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk

2 nov 2025, 21:00 UTC

Ganancias

Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU

2 nov 2025, 21:00 UTC

Ganancias

Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU

2 nov 2025, 21:00 UTC

Ganancias

Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU

2 nov 2025, 20:55 UTC

Ganancias

Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU

2 nov 2025, 20:55 UTC

Ganancias

Westpac FY Institutional Lending Up 17% on Year>WBC.AU

2 nov 2025, 20:55 UTC

Ganancias

Westpac FY Business Lending Up 15% on Year>WBC.AU

2 nov 2025, 20:46 UTC

Ganancias

Westpac Expects Completion in 2H of FY 2026>WBC.AU

2 nov 2025, 20:46 UTC

Ganancias

Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU

2 nov 2025, 20:45 UTC

Ganancias

Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU

2 nov 2025, 20:44 UTC

Ganancias

Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU

2 nov 2025, 20:43 UTC

Ganancias

Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU

2 nov 2025, 20:42 UTC

Ganancias

Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU

2 nov 2025, 20:41 UTC

Ganancias

Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU

2 nov 2025, 20:40 UTC

Ganancias

Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU

2 nov 2025, 20:39 UTC

Ganancias

Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU

2 nov 2025, 20:37 UTC

Ganancias

Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU

2 nov 2025, 20:37 UTC

Ganancias

Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU

2 nov 2025, 20:37 UTC

Ganancias

Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU

2 nov 2025, 20:36 UTC

Ganancias

Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU

2 nov 2025, 20:35 UTC

Ganancias

Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU

2 nov 2025, 20:35 UTC

Ganancias

Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU

2 nov 2025, 20:35 UTC

Ganancias

Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU

2 nov 2025, 20:34 UTC

Ganancias

Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU

2 nov 2025, 20:33 UTC

Ganancias

Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU

2 nov 2025, 14:27 UTC

Ganancias

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

2 nov 2025, 14:25 UTC

Ganancias

Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com

Comparación entre iguales

Cambio de precio

West Pharmaceutical Services Inc previsión

Precio Objetivo

By TipRanks

23.24% repunte

Estimación a 12 Meses

Media 347.63 USD 23.24%

Máximo 375 USD

Mínimo 311 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para West Pharmaceutical Services Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para West Pharmaceutical Services Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

213.26 / 219.27Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

142 / 373 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its products include various primary packaging, containment solutions, reconstitution, and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services, and integrated solutions. The Company’s segments include Proprietary Products and Contract-Manufactured Products. Proprietary Products reportable segment offers proprietary packaging, containment, and drug delivery products, along with analytical lab services and other integrated services. Contract-Manufactured Products segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.